Toxoplasma gondii surface antigen 1 (SAG1) as a potential candidate to develop vaccine against toxoplasmosis: A systematic review

Pagheh, A. S. and Sarvi, S. and Sharif, M. and Rezaei, F. and Ahmadpour, E. and Dodangeh, S. and Omidian, Z. and Hassannia, H. and Mehrzadi, S. and Daryani, A.

Comp Immunol Microbiol Infect Dis (2020) 69: 101414

DOI: 10.1016/j.cimid.2020.101414

Abstract

Toxoplasma gondii is an intracellular parasite that infects a broad range of animal species and humans. As the main surface antigen of the tachyzoite, SAG1 is involved in the process of recognition, adhesion and invasion of host cells. The aim of the current systematic review study is to clarify the latest status of studies in the literature regarding SAG1-associated recombinant proteins or SAG1-associated recombinant DNAs as potential vaccines against toxoplasmosis. Data were systematically collected from six databases including PubMed, Science Direct, Web of Science, Google Scholar, EBSCO and Scopus, up to 1st of January 2019. A total of 87 articles were eligible for inclusion criteria in the current systematic review. The most common antigens used for experimental cocktail vaccines together with SAG1 were ROP2 and SAG2. In addition, the most parasite strains used were RH and ME49. Freund’s adjuvant and cholera toxin have been predominantly utilized. Furthermore, regarding the animal models, route and dose of vaccination, challenge methods, measurement of immune responses and cyst burden have been discussed in the text. Most of these experimental vaccines induce immune responses and have a high degree of protection against parasite infections, increase survival rates and duration and reduce cyst burdens. The data demonstrated that SAG1 antigen has a high potential for use as a vaccine and provided a promising approach for protecting humans and animals against toxoplasmosis.

Citation

Pagheh, A. S., Sarvi, S., Sharif, M., Rezaei, F., Ahmadpour, E., Dodangeh, S., Omidian, Z., Hassannia, H., Mehrzadi, S., & Daryani, A. (2020). Toxoplasma gondii surface antigen 1 (SAG1) as a potential candidate to develop vaccine against toxoplasmosis: A systematic review. Comp Immunol Microbiol Infect Dis, 69, 101414. https://doi.org/10.1016/j.cimid.2020.101414 Animals, Disease Models, Animal, Humans, Mice, Toxoplasma gondii, DNA vaccine, Immunization, Protein vaccine, Protozoan Proteins/*immunology, Toxoplasma/*immunology, Antigens, Protozoan/*immunology, Vaccines, DNA/immunology, Adjuvants, Immunologic, Protozoan Vaccines/*immunology, Sag1, Toxoplasmosis/*prevention & control

Keywords

• Animals
• Disease Models
• Animal
• Humans
• Mice
• Toxoplasma gondii
• DNA vaccine
• Immunization
• Protein vaccine
• Protozoan Proteins/*immunology
• Toxoplasma/*immunology
• Antigens
• Protozoan/*immunology
• Vaccines
• DNA/immunology
• Adjuvants
• Immunologic
• Protozoan Vaccines/*immunology
• Sag1
• Toxoplasmosis/*prevention & control